Framework for Quality Assurance of Ultra-High Dose Rate Clinical Trials Investigating FLASH Effects and Current Technology Gaps
Wei Zou,Rongxiao Zhang,Emil Schüler,Paige A Taylor,Anthony E Mascia,Eric S Diffenderfer,Tianyu Zhao,Ahmet S Ayan,Manju Sharma,Shu-Jung Yu,Weiguo Lu,Walter R Bosch,Christina Tsien,Murat Surucu,Julianne M Pollard-Larkin,Jan Schuemann,Eduardo G Moros,Magdalena Bazalova-Carter,David J Gladstone,Heng Li,Charles B Simone,Kristoffer Petersson,Stephen F Kry,Amit Maity,Billy W Loo,Lei Dong,Peter G Maxim,Ying Xiao,Jeffrey C Buchsbaum,Emil Schueler
DOI: https://doi.org/10.1016/j.ijrobp.2023.04.018
IF: 8.013
2023-04-01
International Journal of Radiation Oncology*Biology*Physics
Abstract:FLASH radiation therapy (FLASH-RT), delivered with ultrahigh dose rate (UHDR), may allow patients to be treated with less normal tissue toxicity for a given tumor dose compared with currently used conventional dose rate. Clinical trials are being carried out and are needed to test whether this improved therapeutic ratio can be achieved clinically. During the clinical trials, quality assurance and credentialing of equipment and participating sites, particularly pertaining to UHDR-specific aspects, will be crucial for the validity of the outcomes of such trials. This report represents an initial framework proposed by the NRG Oncology Center for Innovation in Radiation Oncology FLASH working group on quality assurance of potential UHDR clinical trials and reviews current technology gaps to overcome. An important but separate consideration is the appropriate design of trials to most effectively answer clinical and scientific questions about FLASH. This paper begins with an overview of UHDR RT delivery methods. UHDR beam delivery parameters are then covered, with a focus on electron and proton modalities. The definition and control of safe UHDR beam delivery and current and needed dosimetry technologies are reviewed and discussed. System and site credentialing for large, multi-institution trials are reviewed. Quality assurance is then discussed, and new requirements are presented for treatment system standard analysis, patient positioning, and treatment planning. The tables and figures in this paper are meant to serve as reference points as we move toward FLASH-RT clinical trial performance. Some major questions regarding FLASH-RT are discussed, and next steps in this field are proposed. FLASH-RT has potential but is associated with significant risks and complexities. We need to redefine optimization to focus not only on the dose but also on the dose rate in a manner that is robust and understandable and that can be prescribed, validated, and confirmed in real time. Robust patient safety systems and access to treatment data will be critical as FLASH-RT moves into the clinical trials.
oncology,radiology, nuclear medicine & medical imaging